Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data

Ethan Basch, Amylou Dueck

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction: Patient-reported outcomes (PROs) reflect how patients feel and function as conveyed directly by patients themselves, for example symptoms and physical functioning. PRO measures can be included in any phase of product development as primary, secondary, or exploratory endpoints to understand the impact of treatment on the patient experience. Areas covered: In this review, the authors describe approaches commonly used to assess PROs in drug development programs, including how to select or develop outcomes and measures, implement these in trials, and analyze data. Barriers and facilitators for effectively including PROs in clinical trials are discussed, and strategies for making labeling claims based on PRO data are noted. Expert opinion: Early planning with PRO experts is recommended to assure a successful PRO strategy in a product development program. Outcomes that are meaningful to patients should be rationally identified early in a product development program based on qualitative work, literature search and/or assumed mechanism of action. Measures corresponding to those outcomes should be selected or developed, with demonstration of robust psychometric properties in a related patient population. Ideally, these measures will be tested prior to a pivotal trial to support the design and analysis in the pivotal trial. Selection of timing and mode of assessments should be specified a priori and justified. If a labeling claim is sought, a statistical plan should be pre-specified. Strategies to minimize and handle missing data in analyses should be planned up front.

Original languageEnglish (US)
Pages (from-to)753-758
Number of pages6
JournalExpert Opinion on Drug Discovery
Volume11
Issue number8
DOIs
StatePublished - Aug 2 2016

Fingerprint

Drug Discovery
Safety
Expert Testimony
Patient Reported Outcome Measures
Psychometrics
Outcome Assessment (Health Care)
Clinical Trials
Pharmaceutical Preparations
Population

Keywords

  • Endpoint
  • patient-reported outcome
  • physical function
  • symptom

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Patient-reported outcome measurement in drug discovery : a tool to improve accuracy and completeness of efficacy and safety data. / Basch, Ethan; Dueck, Amylou.

In: Expert Opinion on Drug Discovery, Vol. 11, No. 8, 02.08.2016, p. 753-758.

Research output: Contribution to journalReview article

@article{3612753f8d9a4f2c9b4f728c32e48fa9,
title = "Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data",
abstract = "Introduction: Patient-reported outcomes (PROs) reflect how patients feel and function as conveyed directly by patients themselves, for example symptoms and physical functioning. PRO measures can be included in any phase of product development as primary, secondary, or exploratory endpoints to understand the impact of treatment on the patient experience. Areas covered: In this review, the authors describe approaches commonly used to assess PROs in drug development programs, including how to select or develop outcomes and measures, implement these in trials, and analyze data. Barriers and facilitators for effectively including PROs in clinical trials are discussed, and strategies for making labeling claims based on PRO data are noted. Expert opinion: Early planning with PRO experts is recommended to assure a successful PRO strategy in a product development program. Outcomes that are meaningful to patients should be rationally identified early in a product development program based on qualitative work, literature search and/or assumed mechanism of action. Measures corresponding to those outcomes should be selected or developed, with demonstration of robust psychometric properties in a related patient population. Ideally, these measures will be tested prior to a pivotal trial to support the design and analysis in the pivotal trial. Selection of timing and mode of assessments should be specified a priori and justified. If a labeling claim is sought, a statistical plan should be pre-specified. Strategies to minimize and handle missing data in analyses should be planned up front.",
keywords = "Endpoint, patient-reported outcome, physical function, symptom",
author = "Ethan Basch and Amylou Dueck",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/17460441.2016.1193148",
language = "English (US)",
volume = "11",
pages = "753--758",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Patient-reported outcome measurement in drug discovery

T2 - a tool to improve accuracy and completeness of efficacy and safety data

AU - Basch, Ethan

AU - Dueck, Amylou

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Introduction: Patient-reported outcomes (PROs) reflect how patients feel and function as conveyed directly by patients themselves, for example symptoms and physical functioning. PRO measures can be included in any phase of product development as primary, secondary, or exploratory endpoints to understand the impact of treatment on the patient experience. Areas covered: In this review, the authors describe approaches commonly used to assess PROs in drug development programs, including how to select or develop outcomes and measures, implement these in trials, and analyze data. Barriers and facilitators for effectively including PROs in clinical trials are discussed, and strategies for making labeling claims based on PRO data are noted. Expert opinion: Early planning with PRO experts is recommended to assure a successful PRO strategy in a product development program. Outcomes that are meaningful to patients should be rationally identified early in a product development program based on qualitative work, literature search and/or assumed mechanism of action. Measures corresponding to those outcomes should be selected or developed, with demonstration of robust psychometric properties in a related patient population. Ideally, these measures will be tested prior to a pivotal trial to support the design and analysis in the pivotal trial. Selection of timing and mode of assessments should be specified a priori and justified. If a labeling claim is sought, a statistical plan should be pre-specified. Strategies to minimize and handle missing data in analyses should be planned up front.

AB - Introduction: Patient-reported outcomes (PROs) reflect how patients feel and function as conveyed directly by patients themselves, for example symptoms and physical functioning. PRO measures can be included in any phase of product development as primary, secondary, or exploratory endpoints to understand the impact of treatment on the patient experience. Areas covered: In this review, the authors describe approaches commonly used to assess PROs in drug development programs, including how to select or develop outcomes and measures, implement these in trials, and analyze data. Barriers and facilitators for effectively including PROs in clinical trials are discussed, and strategies for making labeling claims based on PRO data are noted. Expert opinion: Early planning with PRO experts is recommended to assure a successful PRO strategy in a product development program. Outcomes that are meaningful to patients should be rationally identified early in a product development program based on qualitative work, literature search and/or assumed mechanism of action. Measures corresponding to those outcomes should be selected or developed, with demonstration of robust psychometric properties in a related patient population. Ideally, these measures will be tested prior to a pivotal trial to support the design and analysis in the pivotal trial. Selection of timing and mode of assessments should be specified a priori and justified. If a labeling claim is sought, a statistical plan should be pre-specified. Strategies to minimize and handle missing data in analyses should be planned up front.

KW - Endpoint

KW - patient-reported outcome

KW - physical function

KW - symptom

UR - http://www.scopus.com/inward/record.url?scp=84978884509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978884509&partnerID=8YFLogxK

U2 - 10.1080/17460441.2016.1193148

DO - 10.1080/17460441.2016.1193148

M3 - Review article

C2 - 27310432

AN - SCOPUS:84978884509

VL - 11

SP - 753

EP - 758

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 8

ER -